Trastuzumab produces therapeutic actions by upregulating miR-26a and miR-30b in breast cancer cells.
about
MicroRNAs: New Biomarkers for Diagnosis, Prognosis, Therapy Prediction and Therapeutic Tools for Breast CancerOverexpression of miR-30b in the developing mouse mammary gland causes a lactation defect and delays involution3, 3'-Diindolylmethane enhances the effectiveness of herceptin against HER-2/neu-expressing breast cancer cellsModulation of MicroRNA-194 and cell migration by HER2-targeting trastuzumab in breast cancerMicroRNA and HER2-overexpressing cancer.miR-26a suppresses tumor growth and metastasis by targeting FGF9 in gastric cancer.Low expression levels of microRNA-124-5p correlated with poor prognosis in colorectal cancer via targeting of SMC4.MiR-133b is down-regulated in human osteosarcoma and inhibits osteosarcoma cells proliferation, migration and invasion, and promotes apoptosis.RETRACTED: Role of microRNA 30a targeting insulin receptor substrate 2 in colorectal tumorigenesis.Epigenetic silencing of miR-375 induces trastuzumab resistance in HER2-positive breast cancer by targeting IGF1RCritical analysis of the potential for microRNA biomarkers in breast cancer management.Role of microRNA-30c targeting ADAM19 in colorectal cancer.miRNAs regulated by estrogens, tamoxifen, and endocrine disruptors and their downstream gene targets.The bioinformatics analysis of miRNAs signatures differentially expressed in HER2(+) versus HER2(-) breast cancers.mir-30d Regulates multiple genes in the autophagy pathway and impairs autophagy process in human cancer cells.Attenuation of antigenic immunogenicity by kynurenine, a novel suppressive adjuvant.A novel double-negative feedback loop between miR-489 and the HER2-SHP2-MAPK signaling axis regulates breast cancer cell proliferation and tumor growthThe role of miR-26a and miR-30b in HER2+ breast cancer trastuzumab resistance and regulation of the CCNE2 genePARP inhibitor increases chemosensitivity by upregulating miR-664b-5p in BRCA1-mutated triple-negative breast cancer.MicroRNA-26a negatively regulates toll-like receptor 3 expression of rat macrophages and ameliorates pristane induced arthritis in rats.Differential microRNA expression is associated with androgen receptor expression in breast cancerp53-dependent up-regulation of CDKN1A and down-regulation of CCNE2 in response to beryllium.Loss of miR-26a-5p promotes proliferation, migration, and invasion in prostate cancer through negatively regulating SERBP1.miR-30 family promotes migratory and invasive abilities in CD133(+) pancreatic cancer stem-like cells.The role of microRNA-26a in human cancer progression and clinical application.Involvement of microRNAs in HER2 signaling and trastuzumab treatment.The miR-30 family: Versatile players in breast cancer.MiR-199b-5p targets HER2 in breast cancer cells.The Role of MicroRNAs and Human Epidermal Growth Factor Receptor 2 in Proliferative Lupus Nephritis.The regulatory role of IL-6R in hepatitis B-associated fibrosis and cirrhosis.Docosahexaenoic Acid Modulates a HER2-Associated Lipogenic Phenotype, Induces Apoptosis, and Increases Trastuzumab Action in HER2-Overexpressing Breast Carcinoma Cells.Sustained expression of miR-26a promotes chromosomal instability and tumorigenesis through regulation of CHFR.Construction of miRNA-miRNA networks revealing the complexity of miRNA-mediated mechanisms in trastuzumab treated breast cancer cell lines.Electrophoresis separation assisted G-quadruplex DNAzyme-based chemiluminescence signal amplification strategy on a microchip platform for highly sensitive detection of microRNA.Shrimp miR-34 from Shrimp Stress Response to Virus Infection Suppresses Tumorigenesis of Breast Cancer.Preoperative prediction nomogram based on primary tumor miRNAs signature and clinical-related features for axillary lymph node metastasis in early-stage invasive breast cancer.Experimental evidences for miR-30b as a negative regulator of FOXO3 upregulated by kynurenine.Detection and genomic characterization of a mammary-like adenocarcinoma.Predicting and Overcoming Chemotherapeutic Resistance in Breast Cancer.[MicroRNA-26a and Tumor].
P2860
Q26801108-91D9E4B3-68E2-4A92-B0BC-EF1E5471079CQ27317285-518BA4B8-1D58-4BC8-A2F2-7CC7231F406AQ28485231-2BA56CC0-BEC2-4BD1-9DC8-C14E26110A97Q28729012-80D9E96C-62D3-4829-895A-643F81CBDC45Q33994744-2F621F13-B567-4EB4-A78D-7B0A64DE6EC8Q34981594-C6DC9B4E-DCDE-4301-9086-7A8C354201D8Q34982573-FF162D0C-C837-4D78-A1D3-FDFAF1B1E46CQ35082529-97CD05BF-3AC3-4211-8612-9F31913F63ABQ35097075-79EAC1CA-39F5-4823-BE1A-35180A703179Q35103309-B9C9069E-D2F7-4BD6-B650-451743C9A35FQ35137273-493BE0BD-635A-4266-A3F7-33D922F8E54AQ35208955-39275AD1-EA0C-437A-A85A-E76B3A03F5E5Q35912303-7D89F1C2-B43B-45B2-B751-4923EE90BF61Q36533669-71F8DD4E-D9F8-4191-B241-BC059736382AQ36625470-0DA9713D-236D-428C-A499-C8987B17F8AEQ36977755-FA089CB1-D6B0-4BA7-935F-A856E343A6E9Q37109741-1DEAB5E1-968F-4F45-BF2E-5537926EFEABQ37605126-1CA720FD-60F5-48C4-B38D-B9F5FFC7C123Q37630473-2D1C62E5-B6A5-4026-A592-C15081B58CA9Q37689727-377FAE05-7F99-460D-B71A-82EBE868A631Q37707636-28062F0F-1375-435D-B4C2-667D1ED69568Q38733945-75EFD7E1-0B06-4613-911C-5DDD64EBC81AQ38736898-B525AE70-573C-4E50-BC97-45E59935045EQ38787209-1004C767-1198-44D9-9CEF-003C6F3B21A4Q38796729-D376DA69-2C71-4466-825C-99CA0F845C88Q38979308-2342E174-8D7B-48C0-8993-081CEA01FBBDQ39202832-779144DC-6528-4A76-85D9-CDA48C201385Q39214783-CF40B12E-F9E2-428A-A678-59E61BAF3C73Q40283637-2707CF98-87B4-47CF-8796-0BAF0339FCBBQ41663989-90297C61-F4CA-4BB2-B12E-8B973B130862Q41846641-D3100F0F-E862-4F37-8EDB-741E407C2214Q42289696-AC93625E-D91F-4F47-A4CE-696E0B8D5D50Q42370727-F634CED2-226A-456B-8573-96A4E8AC2045Q42676943-9D345B5C-4B74-4F79-BE96-117B747A0585Q47158859-6ABF7C48-3A50-4373-A321-D818579BF6D3Q47790044-D16CCB63-0941-49EC-83AE-E8781EF7AF9EQ47805371-FF6D835C-1783-49FD-9A58-D55003E77D20Q47846945-C0980AFA-DE8B-4666-A9CF-3D1C75CE3FBCQ49544395-38A64A16-9359-455D-BC68-D826AC978AD0Q49790324-9BC08BE1-1ECB-4AB5-8C67-7F43A2700C68
P2860
Trastuzumab produces therapeutic actions by upregulating miR-26a and miR-30b in breast cancer cells.
description
2012 nî lūn-bûn
@nan
2012 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Trastuzumab produces therapeut ...... iR-30b in breast cancer cells.
@ast
Trastuzumab produces therapeut ...... iR-30b in breast cancer cells.
@en
Trastuzumab produces therapeut ...... iR-30b in breast cancer cells.
@nl
type
label
Trastuzumab produces therapeut ...... iR-30b in breast cancer cells.
@ast
Trastuzumab produces therapeut ...... iR-30b in breast cancer cells.
@en
Trastuzumab produces therapeut ...... iR-30b in breast cancer cells.
@nl
prefLabel
Trastuzumab produces therapeut ...... iR-30b in breast cancer cells.
@ast
Trastuzumab produces therapeut ...... iR-30b in breast cancer cells.
@en
Trastuzumab produces therapeut ...... iR-30b in breast cancer cells.
@nl
P2093
P2860
P1433
P1476
Trastuzumab produces therapeut ...... iR-30b in breast cancer cells.
@en
P2093
Fumiaki Sato
Gozoh Tsujimoto
Kazuharu Shimizu
Kazuya Terasawa
Masakazu Toi
Soken Tsuchiya
Takehiro Ichikawa
P2860
P304
P356
10.1371/JOURNAL.PONE.0031422
P407
P577
2012-02-27T00:00:00Z